PierianDx Announces Two New Board Members; Bryan Carey and Frederick Hessler Bring Vast Healthcare Experience
ST LOUIS, MO – PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced that Bryan J. Carey and Frederick A. Hessler have been appointed to the company’s Board of Directors.
Carey, a seasoned healthcare operating executive with significant experience in private equity, currently serves as the executive vice president, CFO and director of Sunspire Health, a network of recovery centers throughout the country. Prior to joining Sunspire, Carey served as the President and CFO of 21st Century Oncology, Managing Director of Vestar Capital Partners, and CFO and Managing Director, Europe, of Aearo Corporation. During his career, Carey completed many significant acquisitions and managed a range of successful portfolio companies in healthcare.
Hessler recently retired from Citigroup, where he led the non-profit healthcare group for 23 years. He currently serves on the boards of Surgical Care Affiliates the LHP Hospital Group, and the American Hospital Association Operations Committee, where he chairs the investment committee. Hessler is also a former board member of MedAssets. Prior to joining Citigroup, Hessler was a partner and Regional Director of Healthcare at Ernst & Young, where he conducted audits, feasibility studies, reorganization plans and strategic planning for a variety of healthcare clients.
“We are absolutely thrilled to have such distinguished industry leaders join our board,” said Ted Briscoe, PierianDx CEO. “Fred and Bryan bring tremendous perspective that will help guide our business and growth strategies.”
“PierianDx has positioned itself to be one of the strategic enablers of personalized medicine,” said Carey. “I look forward to helping them extend their leadership position.”
“PierianDx offers market-tested solutions that advance one of the most pressing strategic goals of health systems today – expanding personalized medicine in order to deliver more precise patient treatments,” said Hessler. “PierianDx is on the forefront of this movement, and I am honored to join their board.”
Hessler and Carey will immediately assume roles on the Board of Directors chaired by Charles Boorady, Managing Partner of Health Catalyst Capital Management. Other board members include John Niederhuber MD, President of Inova Translational Medicine Institute and former COO of the National Cancer Institute, Ted Briscoe, PierianDx CEO, and Rakesh Nagarajan, PierianDx Chief Informatics Officer.
Earlier this year, PierianDx closed $9.25 million Series A financing led by New York- based Health Catalyst Capital Management.
For more information, please visit www.pieriandx.com or @PierianDx on Twitter.
Brad Herrick, firstname.lastname@example.org, 314-238-4476
Jim Howard, SVP, email@example.com, 314-369-7477